28 studies found for:    ev71
Show Display Options
Rank Status Study
1 Not yet recruiting A Clinical Study for Inactivated Vaccine Against EV71
Condition: Enterovirus 71 Human
Interventions: Biological: EV71 with adjuvant aluminium phosphate;   Biological: Placebo
2 Completed A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants
Conditions: Immunogenicity;   Safety
Interventions: Biological: 160U /0.5ml EV71 Vaccine;   Biological: 320U /0.5ml EV71 vaccine;   Biological: 640U /0.5ml EV71 vaccine;   Biological: (without adjuvant) 640U /0.5ml;   Biological: 0/0.5ml placebo
3 Completed An Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine
Condition: Hand, Foot and Mouth Disease
Interventions: Biological: 400U /0.5ml EV71 vaccine;   Biological: 0/0.5ml placebo
4 Completed A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children
Condition: EV71-associated Disease
Interventions: Biological: alum-adjuvant 160U /0.5ml;   Biological: alum-adjuvant 320U /0.5ml;   Biological: alum-adjuvant 640U /0.5ml;   Biological: adjuvant-free 640U /0.5ml;   Biological: 0/0.5ml placebo
5 Completed A Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months
Conditions: Hand, Foot and Mouth Disease;   Herpangina;   Other EV71-associated Diseases
Interventions: Biological: inactivated vaccine (Vero Cell) against EV71;   Biological: 0/0.5ml placebo
6 Enrolling by invitation A Follow-up Study for a Phase III, Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine
Condition: Hand, Foot and Mouth Disease
Intervention: Biological: EV71 vaccine
7 Completed Safety and Immunogenicity of an Inactivated EV71 Vaccine in Infants
Condition: Infection, Viral, Enterovirus
Interventions: Biological: 100U EV71 vaccine with adjuvant;   Biological: 200 U EV71 vaccine with adjuvant;   Biological: 400U EV71 vaccine with adjuvant;   Biological: 200U EV71 vaccine without adjuvant;   Biological: Placebo
8 Completed A Phase II, Safety and Efficacy Study of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants
Condition: The Study Focused on the Safety of Inactivated EV71 Vaccine (Human Diploid Cell) Against Hand, Foot and Mouth Disease in Chinese Children and Infants
Interventions: Biological: 160Eu/0.5ml in infants (6-11 months old);   Biological: 320Eu/0.5ml in infants (6-11 months old);   Biological: 640Eu/0.5ml in infants (6-11 months old);   Biological: 1280Eu/0.5ml (without adjuvant) in infants (6-11 months old);   Biological: 0Eu/0.5ml in infants (6-11 months old);   Biological: 160Eu/0.5ml in infants (12-23 months old);   Biological: 320Eu/0.5ml in infants (12-23 months old);   Biological: 640Eu/0.5ml in infants (12-23 months old);   Biological: 1280Eu/0.5ml (without adjuvant) in infants (12-23 months old);   Biological: 0Eu/0.5ml in infants (12-23 months old);   Biological: 160Eu/0.5ml in children (24 months-5 years old);   Biological: 320Eu/0.5ml in children (24 months-5 years old);   Biological: 640Eu/0.5ml in children (24 months-5 years old);   Biological: 1280Eu/0.5ml (without adjuvant) in children (24 months-5 years old);   Biological: 0Eu/0.5ml in children (24 months-5 years old)
9 Completed A Safety Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults, Children and Infants
Condition: The Study Focused on the Safety of Inactivated EV71 Vaccine (Human Diploid Cell) Against Hand, Foot and Mouth Disease in Chinese Adults, Children and Infants.
Interventions: Biological: 160Eu/0.5ml in adults;   Biological: 320Eu/0.5ml in adults;   Biological: 640Eu/0.5ml in adults;   Biological: 1280Eu/0.5ml (without adjuvant) in 12 adults;   Biological: 0Eu/0.5ml in adults;   Biological: 160Eu/0.5ml in children;   Biological: 320Eu/0.5ml in children;   Biological: 640Eu/0.5ml in children;   Biological: 1280Eu/0.5ml (without adjuvant) in children;   Biological: 0Eu/0.5ml in children;   Biological: 160Eu/0.5ml in infants;   Biological: 320Eu/0.5ml in infants;   Biological: 640Eu/0.5ml in infants;   Biological: 1280Eu/0.5ml (without adjuvant) in infants;   Biological: 0Eu/0.5ml in infants
10 Completed A Protected Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants and Children
Condition: The Efficacy of Inactivated EV71 Vaccine (KMB17) Against HFMD in Chinese Children and Infants
Interventions: Biological: 100U/0.5ml in 6-11 months old infants;   Biological: 100U/0.5ml in 12-23 months old infants;   Biological: 100U/0.5ml in 24-35 months old children;   Biological: 100U/0.5ml in 36-71 months old children
11 Completed Systems Biology of Vaccination for EV71 Vaccine in Humans
Conditions: Systems Biology;   Early Gene;   EV71 Vaccine
Interventions: Biological: 320U /0.5ml;   Biological: 0/0.5ml placebo
12 Completed A Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children
Condition: Hand, Foot and Mouth Disease
Interventions: Biological: vaccine against EV71 of 320U/0.5ml;   Biological: vaccine against EV71 of 640U/0.5ml;   Biological: vaccine against EV71 of 160U/0.5ml
13 Withdrawn Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants
Condition: Infection, Viral, Enterovirus
Intervention: Biological: 400 U EV71 vaccine with adjuvant
14 Completed A Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants
Conditions: Hand, Foot, and Mouth Disease;   Enterovirus Infections
Interventions: Biological: 160U /0.5ml;   Biological: 320U /0.5ml;   Biological: 640U /0.5ml;   Biological: 0/0.5ml placebo
15 Unknown  A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine
Condition: Enterovirus Infection
Intervention: Biological: EV71 vaccine
16 Completed Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine
Condition: Hand, Foot and Mouth Disease
Interventions: Biological: three consecutive lots of EV71 vaccine;   Biological: placebo
17 Completed Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children
Conditions: Hand, Foot and Mouth Disease;   Anti-EV71;   Anti-CVA16
Intervention:
18 Completed Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults
Condition: Infection; Viral, Enterovirus
Interventions: Biological: Inactivated Enterovirus Type 71 Vaccine;   Other: Placebo
19 Unknown  Long Term Outcomes of EV71 CNS Infection
Condition: Central Nervous System Infection
Intervention:
20 Completed Safety of an Inactivated Enterovirus Type 71 Vaccines in Healthy Children
Conditions: Hand-foot-mouth Disease;   Infection; Viral, Enterovirus
Interventions: Biological: 100U inactivated Enterovirus Type 71 Vaccine;   Biological: 200U inactivated Enterovirus Type 71 Vaccine;   Biological: 400U inactivated Enterovirus Type 71 Vaccine;   Biological: Placebo

Previous Page Studies Shown (1-20) Next Page (21-28) Show next page of results
Indicates status has not been verified in more than two years